Shots:
The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved
For the January edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Glioblastoma, the most…
INSIGHTS+
Shots:
Stay up to date with PharmaShots Biosimilars Report, a monthly digest designed to keep you familiarized with the recent developments in biologicsÂ
Biosimilars are cost-effective alternatives to branded drugs but are very much alike when it comes to safety and efficacyÂ
Check out the developments in the Biosimilars with PharmaShots’ illuminating report. PharmaShots has…
Shots:
As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01)
The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases
Propelled by the invaluable…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.
Top 20 Radiopharma Companies Based on Market Cap
Shots:
Integrating scintigraphy with…
Shots:
The EMA approved 3 BLA while 6 New Chemical Entities with 1 recommendation and 1 acceptance in November 2023, leading to treatments for patients and advances in the healthcare industry
In November 2023, the major highlighted drugs were Vyjuvek to Treat Dystrophic Epidermolysis Bullosa (DEB) and Vyvgart with Halozyme’s Enhanze for the treatment of…
Shots:
In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Xtandi and prepared a curated analysis report for our readersÂ
Xtandi is indicated for the treatment of certain prostate cancersÂ
PharmaShots presents a concise take on the key features of Xtandi with…
Shots:
PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, EMA and China. This month’s report includes 3 biological drugs, 12 small molecules, 13 cell and gene therapies, 1 peptide, 3 exosome-based therapy and 4 devicesÂ
Atsena Therapeutics’ capsid AAV.SPR gene therapy, focused on the treatment of Leber congenital…
Shots:
An investment arm of Alphabet Inc., Google Ventures Management Company colossally in seed stage companies, in diverse fields ranging from software and internet to healthcare, life sciences, and artificial intelligence among othersÂ
Since 2016, GV has shifted its focus from seed-stage companies to evolved companies. With over $8B worth of assets under the management…
Shots:
The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023Â
In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…
Shots
To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Â
Continuing the series for the Disease of the Month, PharmaShots brings a condensed report on Pancreatic CancerÂ
November 16th is observed as World Pancreatic Cancer…

